IBM and Novartis are teaming up to improve care and outcomes for breast cancer patients.
In a statement from Novartis, the company will bring its breast cancer knowledge, while IBM will contribute its data analytics and machine learning chops. The collaboration will use real-world data to better understand the expected outcomes of various breast cancer treatments.
The tools that IBM markets help oncologists make treatment decisions for cancer patients and assist the matching of patients to clinical trials. Meanwhile, Novartis who markets four breast cancer drugs, has a number of candidates in its pipeline.
Click here to read the entire article.